Practical Guidance on Optimizing CLL Care in the Era of Molecular Therapies

This comprehensive program gathers CLL management insights from our distinguished CLL experts and features education on emerging and established treatment strategies enhanced by a decision support tool for individualizing these treatments to your patients. All aspects of this program are designed to complement each other, including the interactive treatment decision tool, expert commentaries, and an expert-authored module with downloadable slideset.
Farrukh T. Awan, MD
Ian W. Flinn, MD, PhD
Nicole Lamanna, MD
Susan M. O'Brien, MD


How do you treat patients with newly diagnosed CLL in the era of new agents? In this commentary, Dr. Flinn discusses emerging frontline combination regimens for the treatment of CLL.

Ian W. Flinn, MD, PhD Released: May 3, 2019

Are you aware of some of the latest clinical data in CLL? In this commentary, I will discuss 3 key studies on venetoclax, acalabrutinib, and lisocabtagene maraleucel in CLL that were presented at ASCO 2019.

Susan M. O'Brien, MD Released: June 27, 2019

Farrukh Awan, MD, MS, discusses recent advances and clinical data in CLL that led to an updated online treatment decision support tool for CLL from Clinical Care Options.

Farrukh T. Awan, MD Released: November 13, 2019

Acalabrutinib is now approved for treating patients with CLL. Are you ready to incorporate it into your practice?

Nicole Lamanna, MD Released: January 10, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Produced in collaboration with
CLL Society Logo
Supported by educational grants from
Pharmacyclics LLC, An AbbVie Company
Verastem Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.